52 related articles for article (PubMed ID: 26744522)
1. Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.
Mittal D; Caramia F; Michiels S; Joensuu H; Kellokumpu-Lehtinen PL; Sotiriou C; Loi S; Smyth MJ
Cancer Res; 2016 Jan; 76(2):264-74. PubMed ID: 26744522
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of rat-neu
Sow HS; Benonisson H; Brouwers C; Linssen MM; Camps M; Breukel C; Claassens J; van Hall T; Ossendorp F; Fransen MF; Verbeek JS
Sci Rep; 2020 Mar; 10(1):3933. PubMed ID: 32127568
[TBL] [Abstract][Full Text] [Related]
3. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.
Stagg J; Loi S; Divisekera U; Ngiow SF; Duret H; Yagita H; Teng MW; Smyth MJ
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7142-7. PubMed ID: 21482773
[TBL] [Abstract][Full Text] [Related]
4. CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.
Turcotte M; Allard D; Mittal D; Bareche Y; Buisseret L; José V; Pommey S; Delisle V; Loi S; Joensuu H; Kellokumpu-Lehtinen PL; Sotiriou C; Smyth MJ; Stagg J
Cancer Res; 2017 Oct; 77(20):5652-5663. PubMed ID: 28855210
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 21 and Its Receptor Play a Role in Proliferation, Migration and Invasion of Breast Cancer Cells.
Wang LN; Cui YX; Ruge F; Jiang WG
Cancer Genomics Proteomics; 2015; 12(5):211-21. PubMed ID: 26417024
[TBL] [Abstract][Full Text] [Related]
6. The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.
Phan-Lai V; Dang Y; Gad E; Childs J; Disis ML
Clin Cancer Res; 2016 May; 22(9):2207-16. PubMed ID: 26660518
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
Gall VA; Philips AV; Qiao N; Clise-Dwyer K; Perakis AA; Zhang M; Clifton GT; Sukhumalchandra P; Ma Q; Reddy SM; Yu D; Molldrem JJ; Peoples GE; Alatrash G; Mittendorf EA
Cancer Res; 2017 Oct; 77(19):5374-5383. PubMed ID: 28819024
[TBL] [Abstract][Full Text] [Related]
8. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.
D'Amico L; Menzel U; Prummer M; Müller P; Buchi M; Kashyap A; Haessler U; Yermanos A; Gébleux R; Briendl M; Hell T; Wolter FI; Beerli RR; Truxova I; Radek Š; Vlajnic T; Grawunder U; Reddy S; Zippelius A
J Immunother Cancer; 2019 Jan; 7(1):16. PubMed ID: 30665463
[TBL] [Abstract][Full Text] [Related]
9. PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors.
Charlebois R; Allard B; Allard D; Buisseret L; Turcotte M; Pommey S; Chrobak P; Stagg J
Cancer Res; 2017 Jan; 77(2):312-319. PubMed ID: 27872096
[TBL] [Abstract][Full Text] [Related]
10. Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors.
Nagai Y; Tsuchiya H; Runkle EA; Young PD; Ji MQ; Norton L; Drebin JA; Zhang H; Greene MI
Cell Rep; 2015 Sep; 12(12):2049-59. PubMed ID: 26365188
[TBL] [Abstract][Full Text] [Related]
11. Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies.
Surette A; Yoo BH; Younis T; Matheson K; Rameh T; Snowdon J; Bethune G; Rosen KV
Breast Cancer Res Treat; 2021 Jun; 187(3):743-758. PubMed ID: 33728523
[TBL] [Abstract][Full Text] [Related]
12. ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth.
Liu X; Chipurupalli S; Jiang P; Tavasoli M; Yoo BH; McPhee M; Mazinani S; Francia G; Kerbel RS; Rosen KV
Cell Death Dis; 2022 Aug; 13(8):687. PubMed ID: 35933456
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an
Zeng D; Zhao X; Di L; Lou L; Song Y; Zhang Y; Liu H; Li G
Front Oncol; 2022; 12():918297. PubMed ID: 35875132
[TBL] [Abstract][Full Text] [Related]
14. Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21.
Di Nitto C; Neri D; Weiss T; Weller M; De Luca R
Antibodies (Basel); 2022 Mar; 11(1):. PubMed ID: 35323193
[TBL] [Abstract][Full Text] [Related]
15. Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution.
Kang CC; Ward TM; Bockhorn J; Schiffman C; Huang H; Pegram MD; Herr AE
NPJ Precis Oncol; 2018; 2():10. PubMed ID: 29872719
[TBL] [Abstract][Full Text] [Related]
16. Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.
Guo Y; Hill AA; Ramsey RC; Immermann FW; Corcoran C; Young D; Lavallie ER; Ryan M; Bechard T; Pfeifer R; Warner G; Bologna M; Bloom L; O'Toole M
J Transl Med; 2010 May; 8():50. PubMed ID: 20504348
[TBL] [Abstract][Full Text] [Related]
17. TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter.
Turaj AH; Dahal LN; Beers SA; Cragg MS; Lim SH
Cancer Res; 2017 Jun; 77(12):3376-3378. PubMed ID: 28584185
[No Abstract] [Full Text] [Related]
18. Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough?
Burstein HJ; Schrag D
JAMA; 2017 Jan; 317(1):30-32. PubMed ID: 27918782
[No Abstract] [Full Text] [Related]
19. Immunological effects of chemotherapy in spontaneous breast cancers.
Kroemer G; Galluzzi L; Zitvogel L
Oncoimmunology; 2013 Dec; 2(12):e27158. PubMed ID: 24498568
[No Abstract] [Full Text] [Related]
20. Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.
Blake SJ; Stannard K; Liu J; Allen S; Yong MC; Mittal D; Aguilera AR; Miles JJ; Lutzky VP; de Andrade LF; Martinet L; Colonna M; Takeda K; Kühnel F; Gurlevik E; Bernhardt G; Teng MW; Smyth MJ
Cancer Discov; 2016 Apr; 6(4):446-59. PubMed ID: 26787820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
